To investigate the efficacy of tocilizumab in RA patients with moderate disease activity under biologic therapy
Not Applicable
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000010033
- Lead Sponsor
- Daihei Kida
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who have serious infection 2)Patients who have history of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies 3)Patients who have history of a malignant tumor, or who have malignant tumor 4)Patients who have serious cardiac disease or liver disease, renal damage 5)Pregnant women or women trying to get pregnant 6)Patients considered inappropriate judged by attending physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ow disease activity rate at 24 weeks (SDAI)
- Secondary Outcome Measures
Name Time Method